CD8A and neoplasm: Bevacizumab in combination with atezolizumab increases the number of intra-tumor CD8+ T cells, and increases the expression of intra-tumor chemokine CX3C-ligand1 (CX3CL1) and the CX3CL1 receptor (CX3CR1) on CD8+ T cells (26) and trafficking lymphocytes in metastatic renal cell carcinoma (mRCC) models.